ECP
CLB icon

Epacria Capital Partners’s Core Laboratories CLB Stock Holding History

Epacria Capital Partners’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,860
Closed -$590K – 46
2024
Q3 		$590K Hold
31,860
– – 0.4% 40
2024
Q2 		$646K Hold
31,860
– – 0.47% 40
2024
Q1 		$544K Hold
31,860
– – 0.39% 44
2023
Q4 		$563K Hold
31,860
– – 0.45% 43
2023
Q3 		$765K Hold
31,860
– – 0.63% 40
2023
Q2 		$741K Sell
31,860
-2,353
-7% -$53.2K 0.61% 37
2023
Q1 		$754K Hold
34,213
– – 0.59% 40
2022
Q4 		$693K Buy
+34,213
New +$663K 0.55% 43

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Epacria Capital Partners's CLB Position: Q4 2024 in Review

Epacria Capital Partners sold out of Core Laboratories (CLB) in Q4 2024, closing a stake of 31,860 shares — an estimated $590K sold.

Epacria Capital Partners first reported a position in CLB in Q4 2022 and held it in 8 quarters. The position peaked at $765K in Q3 2023. 209 funds tracked by Wall St. Rank hold CLB as of Q4 2024.

  • Epacria Capital Partners reported no remaining Core Laboratories position as of Q4 2024 after selling out during the quarter.
  • Epacria Capital Partners sold 31,860 Core Laboratories shares in Q4 2024, an estimated $590K.
  • Epacria Capital Partners first reported a position in Core Laboratories in Q4 2022 and held it in 8 quarters.
  • Epacria Capital Partners's Core Laboratories position peaked at $765K in Q3 2023.
  • 209 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2024.

Based on Epacria Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.